Description
The Department of Veterans Affairs (VA) Regional Procurement Office East (RPOE) intends to award a sole source contract to Adaptive Biotechnologies Corporation for the provision of clonoSEQ Measurable Residual Disease (MRD) Testing services. The testing will be provided for the Pittsburgh VA Medical Center, located at University Drive, Pittsburgh, PA 15240. The contract will be firm priced for a five-year period. The clonoSEQ assay is a proprietary, FDA-cleared, patented molecular test developed and performed exclusively by Adaptive Biotechnologies.
• The contract requires the provision of clonoSEQ MRD Testing services for 100 tests per year.
• The testing will be used for MRD detection in bone marrow from patients with multiple myeloma and B-cell acute lymphoblastic leukemia (B-ALL), and in blood or bone marrow from patients with chronic lymphocytic leukemia (CLL).
• Adaptive Biotechnologies is the sole source provider of clonoSEQ MRD testing within the United States.
• The contract will be awarded pursuant to RFO FAR 6.103-1.